An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Guidelines and Recommendations for ADHD in Children and Adolescents [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Oct.
| Brand Name | ||
|---|---|---|
| Available Strengths (mg)* | Average Cost ($)† | |
| Long-Acting Formulations | ||
| Adderall XR (amphetamine mixed salts) | 5, 10, 15, 20, 25, 30 | 82.52 |
| Biphentin (methylphenidate HCl) | 10, 15, 20, 30, 40, 50, 60, 80 | 48.18 |
| Concerta (methylphenidate HCl) | 18, 27, 36, 54 | 73.58 |
| Strattera (atomoxetine) | 10, 18, 25,40, 60, 80, 100 | 93.17 |
| Vyvanse (lisdexamfetamine dimesylate) | 20, 30, 40, 50, 60 | 79.86 |
| Short-Acting and Intermediate-Acting Formulations | ||
| Adderall (amphetamine mixed salts) | 20 | N/A |
| Dexedrine (dexamphetamine sulfate) | 5 | 50.44 |
| Dexedrine Spansule (dextroamphetamine sulphate) | 10, 15 | 46.08 |
| Ritalin (methylphenidate HCl) | 5, 10, 20 | 9.35 |
| Ritalin SR (methylphenidate HCl) | 20 | 14.54 |
Table 1 results were prepared using data from Brogan Inc., a unit of IMS, PharmaStat®, Public Drug Plan databases, 2003–2010, but the analyses, conclusions, opinions and statements expressed are those of CADTH and not of Brogan Inc., a unit of IMS.
Strengths listed include available generic versions.
Average cost (total cost divided by total claims) was calculated using 2010 data.
From: 4, METHODS
This report may be reproduced for non-commercial purposes only and provided appropriate credit is given to CADTH.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
